Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016

  • Significant increase in progression-free survival was observed with nintedanib; this did not translate into an overall survival benefit
  • Learnings from this study will help refine oncology research strategy for the future benefit of patients

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up